Annals of Hematology

, Volume 83, Issue 5, pp 319–321

Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody

  • Yasser Abou Mourad
  • Ali Taher
  • Aref Chehal
  • Ali Shamseddine
Case Report

DOI: 10.1007/s00277-003-0805-z

Cite this article as:
Mourad, Y.A., Taher, A., Chehal, A. et al. Ann Hematol (2004) 83: 319. doi:10.1007/s00277-003-0805-z

Abstract

We report a patient with B-cell prolymphocytic leukemia (PLL) who was treated successfully with the monoclonal anti-CD20 antibody (rituximab). The patient had recurrent infections due to relative neutropenia, secondary to bone marrow infiltration. After treatment with monoclonal anti-CD20 antibodies (rituximab) 375 mg/m2 weekly for 4 weeks, complete remission was obtained. It was documented by normalization of peripheral blood counts, disappearance of organomegaly, and by molecular cytogenetics-fluorescent in situ hybridization (FISH) on bone marrow cells. She remains in complete remission 8 months following the discontinuation of treatment. This is the second reported case of successful treatment of B-cell PLL with rituximab.

Keywords

B-cell prolymphocytic leukemia Monoclonal anti-CD-20 antibody 

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Yasser Abou Mourad
    • 1
  • Ali Taher
    • 1
  • Aref Chehal
    • 1
  • Ali Shamseddine
    • 1
  1. 1.Division of Hematology/Oncology, Department of Internal MedicineAmerican University of Beirut-Medical CenterBeirutLebanon

Personalised recommendations